// App-Quantinova.ai

5060 : Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.

Researchers

Presenter

  • Kurt Miller

Principal Investigators

  • David Cella

  • De Phung

  • Shevani Naidoo

  • Stefan Holmstrom

  • Cristina Ivanescu

  • Konstantina Skaltsa

Medical Centers

  • Department of Urology, Charite Berlin, Berlin, Germany

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Astellas Pharma Europe, Leiden, Netherlands

  • Astellas Pharma Inc., Chertsey, United Kingdom

  • Quintiles, Hoofddorp, Netherlands

  • Quintiles, Barcelona, Spain

Locations

  • Netherlands

  • Germany

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT00974311

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved